EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A WHO International Standard for neutralising antibodies to Chikungunya virus: development and evaluation

Sally A Baylis, Constanze Yue, Marcus Panning, Marie-Christin Pauly, Lia Laura Lewis-Ximenez, Helen M Faddy, Graham Simmons, Michael Busch, Barbara S Schnierle, Hanna Roth, Kay-Martin O Hanschmann, Collaborative Study Group

The Lancet Microbe · 2026-11 · 7 (11) · 101465

DOI: 10.1016/j.lanmic.2026.101465 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Lancet Microbe, 2026-11. Verfasst von Sally A Baylis und 11 weiteren Autor:innen. Beteiligte Einrichtung: Paul-Ehrlich-Institut, Langen, Germany. Electronic address: Sally.Baylis@pei.de. Hauptthemen laut MEDLINE: Chikungunya virus, Antibodies, Viral, Chikungunya Fever, Antibodies, Neutralizing. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Federal Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chikungunya fever is a mosquito-borne disease characterised by severe arthralgia and is caused by chikungunya virus (CHIKV), an alphavirus. The aim of this study was to establish a WHO International Standard for CHIKV-specific neutralising antibodies–a potential correlate of protection.

Methods

Two candidate International Standards (code numbers 1502/19 and 1504/19) were prepared: 1502/19 using plasma from a CHIKV-convalescent individual and 1504/19 using plasma from blood donors from a CHIKV-endemic region. Potencies of the two candidate International Standards were evaluated alongside samples from recovered individuals and donors previously infected with CHIKV, in an international study (2019–20), using a range of virus-neutralisation assays and immunoassays. Statistical analysis was used to estimate mean and relative potencies of the candidate International Standards. Participants included vaccine developers, arbovirus reference laboratories, and diagnostics manufacturers.

Findings

26 laboratories from 12 countries reported detection of anti-CHIKV antibodies and associated potencies. All participants consistently detected both 1502/19 and 1504/19. Overall mean potencies were near-identical for the two candidate International Standards (1502/19, 3·44 log 10 and 1504/19, 3·48 log 10 ). Intra-assay variation was considerably lower than inter-assay variation for the candidate International Standards, which varied by more than 100-fold; this variability was seen for all other anti-CHIKV-positive samples. Assay variability was substantially reduced when antibody titres from the panel of samples were expressed relative to 1502/19 or 1504/19. An agreement was reached to establish 1502/19 as the first WHO International Standard for anti-CHIKV neutralising antibodies, with an assigned unitage of 1000 International Unitage/mL.

Interpretation

The use of the candidate International Standards resulted in harmonisation of anti-CHIKV neutralisation titres, allowing for better comparison of results of neutralisation assays for anti-CHIKV antibodies, either as a consequence of natural infection or produced in response to different vaccines, and will be essential in estimating antibody titres associated with protection against CHIKV. Funding: German Ministry of Health (Bundesministerium für Gesundheit).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chikungunya virusAntibodies, ViralChikungunya FeverAntibodies, NeutralizingHumansWorld Health OrganizationNeutralization TestsReference Standards

Substanzen

Antibodies, ViralAntibodies, Neutralizing

Autor:innen und Institutionen

  • Paul-Ehrlich-Institut, Langen, Germany. Electronic address: Sally.Baylis@pei.de.
  • Paul-Ehrlich-Institut, Langen, Germany.
  • Institute of Virology, Freiburg University Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
  • Institute for Transfusion Medicine and Gene Therapy, Medical Center, University of Freiburg, Freiburg, Germany.
  • Instituto Oswaldo Cruz, Fundaçăo Oswaldo Cruz, Rio de Janeiro, Brazil.
  • School of Health, University of the Sunshine Coast, Petrie, QLD, Australia; Australian Red Cross Lifeblood, Brisbane, QLD, Australia.

Förderung

  • German Federal Ministry of Health

Zitieren

APA

Baylis, S. A., Yue, C., Panning, M., Pauly, M. C., Lewis-Ximenez, L. L., Faddy, H. M., Simmons, G., Busch, M., Schnierle, B. S., Roth, H., Hanschmann, K. O., & Collaborative Study Group (2026). A WHO International Standard for neutralising antibodies to Chikungunya virus: development and evaluation. The Lancet Microbe, 7(11), 101465. https://doi.org/10.1016/j.lanmic.2026.101465

Vancouver

Baylis SA, Yue C, Panning M, Pauly MC, Lewis-Ximenez LL, Faddy HM, et al. A WHO International Standard for neutralising antibodies to Chikungunya virus: development and evaluation. The Lancet Microbe. 2026;7(11):101465. doi:10.1016/j.lanmic.2026.101465

BibTeX
@article{Baylis2026,
  author = {Baylis, Sally A and Yue, Constanze and Panning, Marcus and Pauly, Marie-Christin and Lewis-Ximenez, Lia Laura and Faddy, Helen M and Simmons, Graham and Busch, Michael and Schnierle, Barbara S and Roth, Hanna and Hanschmann, Kay-Martin O and Collaborative Study Group, Collaborative Study Group},
  title = {A WHO International Standard for neutralising antibodies to Chikungunya virus: development and evaluation},
  journal = {The Lancet Microbe},
  year = {2026},
  volume = {7},
  number = {11},
  pages = {101465},
  doi = {10.1016/j.lanmic.2026.101465}
}
Kostenlos starten →